nivolumab,relatlimab
bms
['biomarker', 'nivo', 'relatlimab', 'relativity-047', 'melanoma', 'nivo+rela']
 presenting updates relativity-047 (nivo+relatlimab vs nivo in metastatic #melanoma). subgroup analysis by os, pfs, orr. results are similar across subgroups. the search for biomarkers to guide tx intensity for io (pd1, pd1/lag3, pd1/ctla4) continues. #asco22 
Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.